Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2019

Open Access 01-12-2019 | Research

The role of patient organizations in the rare disease ecosystem in India: an interview based study

Authors: Mohua Chakraborty Choudhury, Gayatri Saberwal

Published in: Orphanet Journal of Rare Diseases | Issue 1/2019

Login to get access

Abstract

Background

Rare diseases (RDs) affect a small percentage of the population but can be severely debilitating and life-threatening. Historically, patient groups (PGs) have been the prime movers in raising awareness about these diseases and advocating for national supportive policies. They have also driven relevant research programs. In India too, PGs have made significant contributions to the national RD ecosystem.

Objective

To assess the contribution of various Indian RD PGs, we carried out an interview-based study of 19organizations. This study aims to highlight the origins and achievements of these groups and the challenges that they have faced. The study also helps to capture the changes in the RD ecosystem that have taken place in recent years.

Result

Of the 19 PGs, two are umbrella organizations, two are other organizations of national scope and 15 are disease specific groups. 14 interviewees were affected by an RD either directly or through a family member. Lack of awareness about RDs in the medical community was the biggest challenge, leading to a delay in diagnosis and subsequent management. Only two out of the 15 conditions have a definitive treatment. However, many of the diseases can be managed with replacement therapies administered for the patient’s entire life, or other supportive therapies. Most diagnostics and treatment regimens that are available globally are now available in India but are expensive and usually available only in a few major cities. These problems are compounded by a lack of medical insurance schemes and government policies to support these patients. The biggest achievement of the PGs was the passing of National Policy for Treatment of Rare Diseases in 2017, unfortunately since put in abeyance. If reinstated, and properly implemented, this policy could significantly improve RD management in the country.

Conclusion

PGs have had a significant role in bringing diagnostics and treatments to India. They have also raised awareness about RDs and related issues such as newborn screening, prenatal diagnostics and genetic counselling. This study highlighted the recommendations of various PGs. The government should address these recommendations and institutionalize the participation of the PGs in formal decision making.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lavandeira A. Orphan drugs: legal aspects, current situation. Haemophilia. 2002;8:194–8.CrossRef Lavandeira A. Orphan drugs: legal aspects, current situation. Haemophilia. 2002;8:194–8.CrossRef
2.
go back to reference Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, et al. Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group. Value Health. 2015;18:906–14.CrossRef Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, et al. Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group. Value Health. 2015;18:906–14.CrossRef
3.
go back to reference Valdez R, Ouyang L, Bolen J. Public Health and Rare Diseases: Oxymoron No More. Prev Chronic Dis. 2016;13:–E05. Valdez R, Ouyang L, Bolen J. Public Health and Rare Diseases: Oxymoron No More. Prev Chronic Dis. 2016;13:–E05.
4.
go back to reference Cohen JS, Biesecker BB. Quality of life in rare genetic conditions: a systematic review of the literature. Am J Med Genet A. 2010;152A:1136–56.CrossRef Cohen JS, Biesecker BB. Quality of life in rare genetic conditions: a systematic review of the literature. Am J Med Genet A. 2010;152A:1136–56.CrossRef
5.
go back to reference Verma BS. Ainhum. A rare disease. Indian J Med Sci. 1967;21:123–5.PubMed Verma BS. Ainhum. A rare disease. Indian J Med Sci. 1967;21:123–5.PubMed
7.
go back to reference Rajasimha HK, Shirol PB, Ramamoorthy P, Hegde M, Barde S, Chandru V, et al. Organization for rare diseases India (ORDI) - addressing the challenges and opportunities for the Indian rare diseases’ community. Genet Res. 2014;96:e009.CrossRef Rajasimha HK, Shirol PB, Ramamoorthy P, Hegde M, Barde S, Chandru V, et al. Organization for rare diseases India (ORDI) - addressing the challenges and opportunities for the Indian rare diseases’ community. Genet Res. 2014;96:e009.CrossRef
8.
go back to reference Tamang R, Singh L, Thangaraj K. Complex genetic origin of Indian populations and its implications. J Biosci. 2012;37:911–9.CrossRef Tamang R, Singh L, Thangaraj K. Complex genetic origin of Indian populations and its implications. J Biosci. 2012;37:911–9.CrossRef
9.
go back to reference Verma IC, Bijarnia S. The burden of genetic disorders in India and a framework for community control. Community Genet. 2002;5:192–6.CrossRef Verma IC, Bijarnia S. The burden of genetic disorders in India and a framework for community control. Community Genet. 2002;5:192–6.CrossRef
10.
go back to reference Bhattacharya S, Katoch VM, Majumder PP, Bhattacharya A. Rare Diseases In India: Current Knowledge and New Possibilities. Proc Indian Natl Sci Acad. 2016;82:1183–7. Bhattacharya S, Katoch VM, Majumder PP, Bhattacharya A. Rare Diseases In India: Current Knowledge and New Possibilities. Proc Indian Natl Sci Acad. 2016;82:1183–7.
11.
go back to reference Kumar H, Sarma P, Medhi B. Orphan drugs: Indian perspective. Indian J Pharmacol. 2017;49:267–9.CrossRef Kumar H, Sarma P, Medhi B. Orphan drugs: Indian perspective. Indian J Pharmacol. 2017;49:267–9.CrossRef
15.
go back to reference Dharssi S, Wong-Rieger D, Harold M, Terry S. Review of 11 national policies for rare diseases in the context of key patient needs. Orphanet J Rare Dis. 2017;12:63.CrossRef Dharssi S, Wong-Rieger D, Harold M, Terry S. Review of 11 national policies for rare diseases in the context of key patient needs. Orphanet J Rare Dis. 2017;12:63.CrossRef
16.
go back to reference Scott DL, Alder S, Usui E, Lui K. Orphan Drug Programs/Policies in Australia, Japan, and Canada. Drug Inf J. 2001;35:1–16.CrossRef Scott DL, Alder S, Usui E, Lui K. Orphan Drug Programs/Policies in Australia, Japan, and Canada. Drug Inf J. 2001;35:1–16.CrossRef
17.
go back to reference Young A, Menon D, Street J, Al-Hertani W, Stafinski T. Exploring patient and family involvement in the lifecycle of an orphan drug: a scoping review. Orphanet J Rare Dis. 2017;12:188.CrossRef Young A, Menon D, Street J, Al-Hertani W, Stafinski T. Exploring patient and family involvement in the lifecycle of an orphan drug: a scoping review. Orphanet J Rare Dis. 2017;12:188.CrossRef
18.
go back to reference Mascalzoni D, Petrini C, Taruscio D, Gainotti S. The Role of Solidarity(−ies) in Rare Diseases Research. Adv Exp Med Biol. 2017;1031:589–604.CrossRef Mascalzoni D, Petrini C, Taruscio D, Gainotti S. The Role of Solidarity(−ies) in Rare Diseases Research. Adv Exp Med Biol. 2017;1031:589–604.CrossRef
19.
go back to reference Mikami K, Sturdy S. Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshop. Res Involv Engagem. 2017;3:14.CrossRef Mikami K, Sturdy S. Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshop. Res Involv Engagem. 2017;3:14.CrossRef
20.
go back to reference Terry SF, Terry PF, Rauen KA, Uitto J, Bercovitch LG. Science and society: Advocacy groups as research organizations: the PXE International example. Nat Rev Genet. 2007;8:157.CrossRef Terry SF, Terry PF, Rauen KA, Uitto J, Bercovitch LG. Science and society: Advocacy groups as research organizations: the PXE International example. Nat Rev Genet. 2007;8:157.CrossRef
22.
go back to reference Koay PP, Sharp RR. The role of patient advocacy organizations in shaping genomic science. Annu Rev Genomics Hum Genet. 2013;14:579–95.CrossRef Koay PP, Sharp RR. The role of patient advocacy organizations in shaping genomic science. Annu Rev Genomics Hum Genet. 2013;14:579–95.CrossRef
23.
go back to reference Forsythe LP, Szydlowski V, Murad MH, Ip S, Wang Z, Elraiyah TA, et al. A systematic review of approaches for engaging patients for research on rare diseases. J Gen Intern Med. 2014;29(Suppl 3):S788–800.CrossRef Forsythe LP, Szydlowski V, Murad MH, Ip S, Wang Z, Elraiyah TA, et al. A systematic review of approaches for engaging patients for research on rare diseases. J Gen Intern Med. 2014;29(Suppl 3):S788–800.CrossRef
24.
go back to reference Sireau NT. Developing a cure for Black Bone Disease. Orphanet J Rare Dis. 2012;7:A37.CrossRef Sireau NT. Developing a cure for Black Bone Disease. Orphanet J Rare Dis. 2012;7:A37.CrossRef
26.
go back to reference Akkermans R. Patient groups drive research for lymphangiomyomatosis. Lancet Respir Med. 2013;1:443–4.CrossRef Akkermans R. Patient groups drive research for lymphangiomyomatosis. Lancet Respir Med. 2013;1:443–4.CrossRef
27.
go back to reference Anand G. The Cure. Penguin Random House India Private Limited; 2010. Anand G. The Cure. Penguin Random House India Private Limited; 2010.
28.
go back to reference Pinto D, Martin D, Chenhall R. The involvement of patient organisations in rare disease research: a mixed methods study in Australia. Orphanet J Rare Dis. 2016;11:2.CrossRef Pinto D, Martin D, Chenhall R. The involvement of patient organisations in rare disease research: a mixed methods study in Australia. Orphanet J Rare Dis. 2016;11:2.CrossRef
29.
go back to reference Wästfelt M, Fadeel B, Henter J-I. A journey of hope: lessons learned from studies on rare diseases and orphan drugs. J Intern Med. 2006;260:1–10.CrossRef Wästfelt M, Fadeel B, Henter J-I. A journey of hope: lessons learned from studies on rare diseases and orphan drugs. J Intern Med. 2006;260:1–10.CrossRef
30.
go back to reference Aymé S, Kole A, Groft S. Empowerment of patients: lessons from the rare diseases community. Lancet. 2008;371:2048–51.CrossRef Aymé S, Kole A, Groft S. Empowerment of patients: lessons from the rare diseases community. Lancet. 2008;371:2048–51.CrossRef
31.
go back to reference Mohanty D, Colah RB, Gorakshakar AC, Patel RZ, Master DC, Mahanta J, et al. Prevalence of β-thalassemia and other haemoglobinopathies in six cities in India: a multicentre study. J Community Genet. 2013;4:33–42.CrossRef Mohanty D, Colah RB, Gorakshakar AC, Patel RZ, Master DC, Mahanta J, et al. Prevalence of β-thalassemia and other haemoglobinopathies in six cities in India: a multicentre study. J Community Genet. 2013;4:33–42.CrossRef
32.
go back to reference Bhattacharya S, Khadilkar SV, Nalini A, Ganapathy A, Mannan AU, Majumder PP, et al. Mutation Spectrum of GNE Myopathy in the Indian Sub-Continent. J Neuromuscul Dis. 2018;5:85–92.CrossRef Bhattacharya S, Khadilkar SV, Nalini A, Ganapathy A, Mannan AU, Majumder PP, et al. Mutation Spectrum of GNE Myopathy in the Indian Sub-Continent. J Neuromuscul Dis. 2018;5:85–92.CrossRef
33.
go back to reference Hamblin T, Kaul S, Dalvi UA. Approaches to therapy for children in India with cerebral palsy. J Pediatr Rehabil Med. 2008;1:169–74.PubMed Hamblin T, Kaul S, Dalvi UA. Approaches to therapy for children in India with cerebral palsy. J Pediatr Rehabil Med. 2008;1:169–74.PubMed
34.
go back to reference Verma IC. Burden of genetic disorders in India. Indian J Pediatr. 2000;67:893–8.CrossRef Verma IC. Burden of genetic disorders in India. Indian J Pediatr. 2000;67:893–8.CrossRef
35.
go back to reference Muranjan M, Karande S. Enzyme replacement therapy in India: Lessons and insights. J Postgrad Med. 2018;64:195–9.CrossRef Muranjan M, Karande S. Enzyme replacement therapy in India: Lessons and insights. J Postgrad Med. 2018;64:195–9.CrossRef
37.
go back to reference Dunkle M. A 30-year retrospective: National Organization for Rare Disorders, the Orphan Drug Act, and the role of rare disease patient advocacy groups. Orphan Drugs: Research & Reviews. 2014;4:19–27.CrossRef Dunkle M. A 30-year retrospective: National Organization for Rare Disorders, the Orphan Drug Act, and the role of rare disease patient advocacy groups. Orphan Drugs: Research & Reviews. 2014;4:19–27.CrossRef
38.
go back to reference Best RK. Disease Politics and Medical Research Funding: Three Ways Advocacy Shapes Policy. Am Sociol Rev. 2012;77:780–803.CrossRef Best RK. Disease Politics and Medical Research Funding: Three Ways Advocacy Shapes Policy. Am Sociol Rev. 2012;77:780–803.CrossRef
42.
go back to reference Auvin S, Irwin J, Abi-Aad P, Battersby A. The Problem of Rarity: Estimation of Prevalence in Rare Disease. Value Health. 2018;21:501–7.CrossRef Auvin S, Irwin J, Abi-Aad P, Battersby A. The Problem of Rarity: Estimation of Prevalence in Rare Disease. Value Health. 2018;21:501–7.CrossRef
43.
go back to reference Grow K, Vashist M, Abrol P, Sharma S, Yadav R. Beta thalassemia in India: current status and the challenges ahead. Int J Pharm Pharm Sci. 2014;6:28–33. Grow K, Vashist M, Abrol P, Sharma S, Yadav R. Beta thalassemia in India: current status and the challenges ahead. Int J Pharm Pharm Sci. 2014;6:28–33.
44.
go back to reference Taylor CM, Karet Frankl FE. Developing a strategy for the management of rare diseases. BMJ. 2012;344:e2417.CrossRef Taylor CM, Karet Frankl FE. Developing a strategy for the management of rare diseases. BMJ. 2012;344:e2417.CrossRef
46.
go back to reference Betancourt JR, Green AR, Carrillo JE, Ananeh-Firempong O 2nd. Defining cultural competence: a practical framework for addressing racial/ethnic disparities in health and health care. Public Health Rep. 2003;118:293–302.CrossRef Betancourt JR, Green AR, Carrillo JE, Ananeh-Firempong O 2nd. Defining cultural competence: a practical framework for addressing racial/ethnic disparities in health and health care. Public Health Rep. 2003;118:293–302.CrossRef
47.
go back to reference Arcaya MC, Arcaya AL, Subramanian SV. Inequalities in health: definitions, concepts, and theories. Glob Health Action. 2015;8:27106.CrossRef Arcaya MC, Arcaya AL, Subramanian SV. Inequalities in health: definitions, concepts, and theories. Glob Health Action. 2015;8:27106.CrossRef
48.
go back to reference Mamidala MP, Kalikiri MK, Praveen Kumar PTV, Rajesh N, Vallamkonda OR, Rajesh V. Consanguinity in India and its association with autism spectrum disorder. Autism Res. 2015;8:224–8.CrossRef Mamidala MP, Kalikiri MK, Praveen Kumar PTV, Rajesh N, Vallamkonda OR, Rajesh V. Consanguinity in India and its association with autism spectrum disorder. Autism Res. 2015;8:224–8.CrossRef
49.
go back to reference Kumar R, Arya V, Agarwal S. Profiling β Thalassemia Mutations in Consanguinity and Nonconsanguinity for Prenatal Screening and Awareness Programme. Adv Hematol. 2015;2015:625721.CrossRef Kumar R, Arya V, Agarwal S. Profiling β Thalassemia Mutations in Consanguinity and Nonconsanguinity for Prenatal Screening and Awareness Programme. Adv Hematol. 2015;2015:625721.CrossRef
51.
go back to reference Sharma S, Seth B, Jawade P, Ingale M, Setia MS. Quality of Life in Children with Thalassemia and their Caregivers in India. Indian J Pediatr. 2017;84:188–94.CrossRef Sharma S, Seth B, Jawade P, Ingale M, Setia MS. Quality of Life in Children with Thalassemia and their Caregivers in India. Indian J Pediatr. 2017;84:188–94.CrossRef
52.
go back to reference Kumar A, Jaryal A, Gulati S, Chakrabarty B, Singh A, Deepak KK, et al. Cardiovascular Autonomic Dysfunction in Children and Adolescents With Rett Syndrome. Pediatr Neurol. 2017;70:61–6.CrossRef Kumar A, Jaryal A, Gulati S, Chakrabarty B, Singh A, Deepak KK, et al. Cardiovascular Autonomic Dysfunction in Children and Adolescents With Rett Syndrome. Pediatr Neurol. 2017;70:61–6.CrossRef
53.
go back to reference Domecq JP, Prutsky G, Elraiyah T, Wang Z, Nabhan M, Shippee N, et al. Patient engagement in research: a systematic review. BMC Health Serv Res. 2014;14:89.CrossRef Domecq JP, Prutsky G, Elraiyah T, Wang Z, Nabhan M, Shippee N, et al. Patient engagement in research: a systematic review. BMC Health Serv Res. 2014;14:89.CrossRef
54.
go back to reference Julkowska D, Austin CP, Cutillo CM, Gancberg D, Hager C, Halftermeyer J, et al. The importance of international collaboration for rare diseases research: a European perspective. Gene Ther. 2017;24:562–71.CrossRef Julkowska D, Austin CP, Cutillo CM, Gancberg D, Hager C, Halftermeyer J, et al. The importance of international collaboration for rare diseases research: a European perspective. Gene Ther. 2017;24:562–71.CrossRef
55.
go back to reference Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJC, et al. Current status of newborn screening worldwide: 2015. Semin Perinatol. 2015;39:171–87.CrossRef Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJC, et al. Current status of newborn screening worldwide: 2015. Semin Perinatol. 2015;39:171–87.CrossRef
58.
go back to reference van de Bovenkamp HM, Trappenburg MJ, Grit KJ. Patient participation in collective healthcare decision making: the Dutch model. Health Expect. 2010;13:73–85.CrossRef van de Bovenkamp HM, Trappenburg MJ, Grit KJ. Patient participation in collective healthcare decision making: the Dutch model. Health Expect. 2010;13:73–85.CrossRef
Metadata
Title
The role of patient organizations in the rare disease ecosystem in India: an interview based study
Authors
Mohua Chakraborty Choudhury
Gayatri Saberwal
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2019
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-019-1093-6

Other articles of this Issue 1/2019

Orphanet Journal of Rare Diseases 1/2019 Go to the issue